Diclofenac for uveitic macular edama

Not Applicable

• Conditions: Degeneration of macula and posterior pole, Other specified retinal disorders; H20, H22,H; H35.3, H35; Condition 1: uveitis. Condition 2: cystoid macular edama.; Iridocyclitis, Disorders of iris and ciliary body in diseases classified elsewhere, Posterior cyclitis

• Registration Number: IRCT2016042727642N1
• Lead Sponsor: Isfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

CME resistant to treatment in one or both eyes; Full control of intraocular inflammation; Visual aquity between 20/50 and 5/200; No intraocular or periocular injection during the last 6 month; No previous history of glaucoma or ocular hypertension; No history of previous ocular surgery.
Exclusion criteria: Monocular patient; Patients with significant media opacity; Other diseases of the retina with macular involvement; Pregnancy; Drug hypersensitivity to diclofenac.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Visual Aquity. Timepoint: Before, one week and 4 week after intervention. Method of measurement: Snelen Chart- Log MAR.;Central Macular Thickness. Timepoint: Before, one week and 4 week after intervention. Method of measurement: OCT.

Secondary Outcome Measures

Name	Time	Method
Intra Ocular Pressure. Timepoint: Before, one week and 4 week after intervention. Method of measurement: Goldman tonometer, mmHg.;Lens opacity. Timepoint: Before, one week and 4 week after intervention. Method of measurement: Examination.